Rising Stress and
Depression are contributing to the growth of the European Schizophrenia Drugs
Market

European schizophrenia
drug market is estimated to grow at a CAGR of 1.5%, during the forecast
period (2024-2031). The market growth is driven by the increasing number of
mental health disorders. Additionally, the government policies in the region
for mental health promote market growth. The European schizophrenia drug market
is segmented by therapeutic class
(second-generation antipsychotics, third-generation antipsychotics, and others)
and by treatment (oral and injectables).

Get Free Sample link @ https://www.omrglobal.com/request-sample/european-schizophrenia-drugs-market

Market Dynamics           

·       
The oral segment is anticipated to
hold the largest market share during the forecast period, owing to the increase in the
prevalence of anxiety and depression.

·       
The injectable segment is expected to project considerable
growth attributed to an increase in R&D for injectable drugs and new
product launches.

·       
The second-generation segment dominated the market, owing
to the availability of multiple products and the increasing prevalence of
mental disorders.

·       
 The third-generation segment is expected
to project considerable growth attributed to the new
product approvals and product launches in the segment.

 The companies that are
contributing to the growth of the European schizophrenia drugs market include
Allergan PLC, Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca
PLC, and Johnson & Johnson Services, Inc. The market players are contributing
significantly to the market growth by the adoption of various strategies
including new product launches, mergers and acquisitions, collaborations with
the government, funding for start-ups, and technological advancements.

Inquiry Before Buying of European
Schizophrenia Drugs Market Report @ https://www.omrglobal.com/inquiry-before-buying/european-schizophrenia-drugs-market

Recent Developments

·       
In September 2024, Teva Pharmaceuticals presented
data informing clinical strategies for switching patients to UZEDY^®, at the 37th Annual European College of
Neuropsychopharmacology (ECNP) Congress, in Italy. UZEDY^® is an extended-release injectable suspension of risperidone
for subcutaneous use every one or two months for the treatment of schizophrenia
in adults.

·       
In September 2024, the US Food and Drug
Administration (FDA) approved Cobenfy (xanomeline and trospium chloride) for
schizophrenia in adults. The first UK trial of the compound is planned in
Oxford, in 2025.

·       
In March 2024, Otsuka
Pharmaceutical Co., Ltd announced that the European Commission (EC) has
approved Abilify Maintena^® 720mg/960mg (aripiprazole). The drug
is prescribed as a once-every-two-month Long-Acting Injectable (LAI)
formulation for the maintenance treatment of schizophrenia in adult patients
stabilized with aripiprazole. The drug is accepted by all European Union (EU)
member states, and Iceland, Norway, and Liechtenstein.

Reasons to Buying From
us -



1. We cover more than 15 major industries, further segmented into more than 90
sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after
purchasing your report.

For More Information or
Query, Visit @ https://www.omrglobal.com/industry-reports/european-schizophrenia-drugs-market

Media Contact:



Contact Person: Mr. Anurag Tiwari

Email: anurag@omrglobal.com

Contact no: +91 780-304-0404

Company Name: Orion Market Research



About Orion Market Research



Orion Market Research (OMR) is a market research and consulting company known
for its crisp and concise reports. The company is equipped with an experienced
team of analysts and consultants. OMR offers quality syndicated research
reports, customized research reports, consulting and other research-based
services. The company also offers Digital Marketing services through its
subsidiary OMR Digital and Software development and Consulting Services through
another subsidiary Encanto Technologies.